Author

J. Pons

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

A. Banuelos· 1 shared A. Barkal· 1 shared A. Delaidelli· 1 shared A. He· 1 shared A. Tousley· 1 shared A. Westhorpe· 1 shared A.-K. Mehnert· 1 shared B. A. Smith· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Banuelos

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Hepatitis E Virus-induced antiviral response by plasmacytoid dendritic cells is modulated by the ORF2 protein

G. Joshi, E. Decembre, J. Brocard, C. Montpellier, M. Ferrie, O. Allatif, A.-K. Mehnert, J. Pons, D. Galiana, V. L. Dao Thi, N. Jouvenet, L. Cocquerel, M. Dreux

This study shows that Hepatitis E Virus (HEV) ORF2 protein modulates plasmacytoid dendritic cell (pDC)-mediated antiviral responses by affecting pDC recognition of infected cells.

bioRxiv · Apr 12, 2024Immunology

Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: results of preclinical efficacy testing

S. K. Menzies, T. Litschka-Koen, R. J. Edge, J. Alsolaiss, E. Crittenden, S. R. Hall, A. Westhorpe, B. Thomas, J. Murray, N. Shongwe, S. Padidar, D. G. Lalloo, N. R. Casewell, J. Pons, R. A. Harrison

This study evaluates two antivenoms as alternatives to SAIMR Polyvalent in Eswatini, finding they are equally or more effective against the most common snake venom but less effective against others.

bioRxiv · May 16, 2022Pharmacology & Toxicology

Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication

J. Theruvath, M. Menard, B. A. Smith, M. H. Linde, G. Coles, W. Wu, L. Kiru, A. Delaidelli, J. L. Silberstein, A. Banuelos, S. Dhingra, E. Sotillo, S. Heitzeneder, A. Tousley, J. Lattin, , R. G. Majzner

This study shows that combining anti-GD2 and anti-CD47 antibodies enhances anti-tumor responses by recruiting macrophages and disrupting the GD2:Siglec-7 interaction in GD2+ cancers.

bioRxiv · Mar 19, 2021 · PreprintImmunology